S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NYSE:MD

MEDNAX (MD) Stock Forecast, Price & News

$18.50
+0.07 (+0.38%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$18.12
$18.79
50-Day Range
$17.53
$24.34
52-Week Range
$17.17
$35.67
Volume
754,666 shs
Average Volume
857,609 shs
Market Capitalization
$1.61 billion
P/E Ratio
17.29
Dividend Yield
N/A
Beta
2.05
30 days | 90 days | 365 days | Advanced Chart
Receive MD News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDNAX and its competitors with MarketBeat's FREE daily newsletter.

MEDNAX logo

About MEDNAX

MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of February 17, 2022, it operated a network of approximately 2,700 physicians. The company was founded in 1979 and is based in Sunrise, Florida.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Hospitals
Sub-Industry
Health Care Services
Sector
Medical
CUSIP
58502B10
Employees
5,000
Year Founded
1979

Sales & Book Value

Annual Sales
$1.91 billion
Cash Flow
$1.93 per share
Book Value
$10.05 per share

Profitability

Net Income
$130.96 million
Pretax Margin
5.47%

Debt

Price-To-Earnings

Miscellaneous

Free Float
84,818,000
Market Cap
$1.61 billion
Optionable
Optionable

Company Calendar

Last Earnings
4/28/2022
Today
5/21/2022
Next Earnings (Estimated)
8/05/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

1.90 out of 5 stars

Medical Sector

693rd out of 1,416 stocks

Hospitals Industry

4th out of 5 stocks

Analyst Opinion: 3.1Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













MEDNAX (NYSE:MD) Frequently Asked Questions

Is MEDNAX a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEDNAX stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MD, but not buy additional shares or sell existing shares.
View analyst ratings for MEDNAX
or view top-rated stocks.

When is MEDNAX's next earnings date?

MEDNAX is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for MEDNAX
.

How were MEDNAX's earnings last quarter?

MEDNAX, Inc. (NYSE:MD) issued its quarterly earnings data on Thursday, April, 28th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.06. The firm had revenue of $482.20 million for the quarter, compared to analysts' expectations of $471.29 million. MEDNAX had a net margin of 4.73% and a trailing twelve-month return on equity of 15.64%. The firm's revenue was up 7.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.20 EPS.
View MEDNAX's earnings history
.

What price target have analysts set for MD?

6 brokerages have issued 12-month price targets for MEDNAX's stock. Their forecasts range from $16.00 to $31.00. On average, they expect MEDNAX's share price to reach $26.50 in the next twelve months. This suggests a possible upside of 43.2% from the stock's current price.
View analysts' price targets for MEDNAX
or view top-rated stocks among Wall Street analysts.

Who are MEDNAX's key executives?
MEDNAX's management team includes the following people:
  • Mr. Mark S. Ordan, CEO & Director (Age 63, Pay $3.35M)
  • Dr. Roger J. Medel M.D., Co-Founder & Director (Age 75, Pay $50.99k)
  • Mr. C. Marc Richards, Exec. VP & CFO (Age 51, Pay $1.29M)
  • Mr. John C. Pepia, Sr. VP & Chief Accounting Officer (Age 59, Pay $931.2k)
  • Mr. Dominic J. Andreano, Exec. VP, Gen. Counsel & Sec. (Age 53, Pay $1.29M)
  • Ms. Mary Ann E. Moore, Exec. VP and Chief Enterprise Risk & Legal Operations Officer (Age 62, Pay $3.21M)
  • Ms. Cheryl M. VanPattan, Sr. VP & Chief Information Officer
  • Mr. Charles W. Lynch C.F.A., Sr. VP of Fin., Strategy & Investor Relations
  • Ms. Dana Dreher-Rodwell, VP & Chief Compliance Officer
  • Ms. Meghan K. Lublin, Sr. VP and Chief Marketing & Communications Officer
What is Mark S. Ordan's approval rating as MEDNAX's CEO?

6 employees have rated MEDNAX CEO Mark S. Ordan on Glassdoor.com. Mark S. Ordan has an approval rating of 34% among MEDNAX's employees. This puts Mark S. Ordan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of MEDNAX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MEDNAX investors own include NVIDIA (NVDA), AbbVie (ABBV), QUALCOMM (QCOM), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T), Walt Disney (DIS), Wells Fargo & Company (WFC), Exxon Mobil (XOM) and Advanced Micro Devices (AMD).

What is MEDNAX's stock symbol?

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

Who are MEDNAX's major shareholders?

MEDNAX's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.04%), Vanguard Group Inc. (10.94%), Earnest Partners LLC (7.40%), Dimensional Fund Advisors LP (4.12%), Lazard Asset Management LLC (3.74%) and State Street Corp (3.61%). Company insiders that own MEDNAX stock include John C Pepia, Mark S Ordan, Nicholas J Nikolopoulos, Roger Mack Hinson and Roger Md Medel.
View institutional ownership trends for MEDNAX
.

Which major investors are selling MEDNAX stock?

MD stock was sold by a variety of institutional investors in the last quarter, including Foundry Partners LLC, Earnest Partners LLC, State Street Corp, JPMorgan Chase & Co., Vident Investment Advisory LLC, Granite Investment Partners LLC, Northern Trust Corp, and Bank of New York Mellon Corp. Company insiders that have sold MEDNAX company stock in the last year include John C Pepia, Mark S Ordan, Roger Mack Hinson, and Roger Md Medel.
View insider buying and selling activity for MEDNAX
or view top insider-selling stocks.

Which major investors are buying MEDNAX stock?

MD stock was bought by a variety of institutional investors in the last quarter, including River Road Asset Management LLC, Lazard Asset Management LLC, Vanguard Group Inc., Renaissance Technologies LLC, Raymond James & Associates, Wellington Management Group LLP, Engineers Gate Manager LP, and Qube Research & Technologies Ltd.
View insider buying and selling activity for MEDNAX
or or view top insider-buying stocks.

How do I buy shares of MEDNAX?

Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MEDNAX's stock price today?

One share of MD stock can currently be purchased for approximately $18.50.

How much money does MEDNAX make?

MEDNAX has a market capitalization of $1.61 billion and generates $1.91 billion in revenue each year. The company earns $130.96 million in net income (profit) each year or $1.07 on an earnings per share basis.

How many employees does MEDNAX have?

MEDNAX employs 5,000 workers across the globe.

When was MEDNAX founded?

MEDNAX was founded in 1979.

What is MEDNAX's official website?

The official website for MEDNAX is www.mednax.com.

How can I contact MEDNAX?

MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at (954) 384-0175, via email at [email protected]om, or via fax at 954-838-9961.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.